Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314812 | 0.74 | — | — | |
| SCHEMBL22082541 | 0.74 | — | — | |
| SCHEMBL18483159 | 0.74 | — | — | |
| SCHEMBL1723919 | 0.74 | — | — | |
| SCHEMBL28437217 | 0.74 | — | — | |
| SCHEMBL22508331 | 0.74 | — | — | |
| SCHEMBL15219234 | 0.73 | APLNR (0.38) | LMNAALOX15BLMPMP22TDP1 | |
| SCHEMBL4644937 | 0.73 | APLNR (0.38) | LMNAALOX15BLMPMP22TDP1 | |
| Hydrochloric Acid SCHEMBL4621231 | 0.72 | — | — | |
| SCHEMBL9017773 | 0.72 | NPSR1 (0.37) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027599-A1 | 1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-08 | — | — | EP | claimed |
| WO-2015014446-A1 | 1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3027599-A1 | 1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014446-A1 | 1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PKM 675/4885EPHX1 1946/4885LMNA 2924/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | PKM 675/4885EPHX1 1946/4885LMNA 2924/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PKM 675/4885EPHX1 1946/4885LMNA 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.